Up-regulation of both KMO and KYNU in glioma may lead to increased production of 3-HK and 3-HAA, which may contribute to creating an immunosuppressive micromilieu by accumulating tryptophan toxic metabolites. The gene discussed is KMO; the disease is glioma.